The direct route may not be the best way to home

Journal of Nuclear Medicine

Volumn 46, Issue 3, 2005, Pages 391-394

  Sharkey, Robert M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTIN; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN; PENTETIC ACID; RADIOISOTOPE; TUMOR ANTIGEN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; TUMOR MARKER;

AUTORADIOGRAPHY; BLOOD VESSEL PERMEABILITY; COLORECTAL CANCER; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOLOGY; KIDNEY CANCER; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PLASMA CLEARANCE; PRIORITY JOURNAL; RADIOACTIVITY; REVIEW; TUMOR LOCALIZATION; TUMOR SCINTISCANNING; TUMOR XENOGRAFT; ANIMAL; DRUG DELIVERY SYSTEM; IMMUNOASSAY; METABOLISM; METHODOLOGY; NEOPLASM; NOTE; RADIOIMMUNOTHERAPY; SCINTISCANNING;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOASSAY; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TUMOR MARKERS, BIOLOGICAL;

EID: 17844388615     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther. 2002; 1:553-563.
2. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med. 2003;44:400-411.
3. Stickney DR, Anderson LD, Slater JB, et al. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991;51:6650-6655.
4. Goldenberg DM, Goldenberg H, Sharkey RM, et al. Imaging of colorectal carcinoma with radiolabeled antibodies. Semin Nucl Med. 1989;19:262-281.
5. Paganelli G, Pervez S, Siccardi AG, et al. Intra-peritoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer. 1990;45:1184-1189.
6. Le Doussal JM, Chetanneau A, Gruaz-Guyon A, et al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J Nucl Med. 1993;34:1662-1671.
7. 90Y radioimmunotherapy in a mouse xenograft model [abstract]. J Immunother. 1994;16:158.
8. Gautherot E, Bouhou J, Le Doussal JM, et al. Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer. 1997;80(suppl):2618-2623.
9. 2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin Cancer Res. 1999;5(suppl):3183s-3189s.
10. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA. 2000;97:1802-1807.
11. 131I- labeled bivalent hapten. J Nucl Med. 2000;41:480-487.
12. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535-2543.
13. 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″, N‴-tetraacetic acid (DOTA)-biotin. Cancer Res. 2002;62: 5755-5760.
14. Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100:208-216.
15. Grana C, Chinol M, Robertson C, et al. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br J Cancer. 2002;86:207-212.
16. Subbiah K, Hamlin DK, Pagel JM, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med. 2003;44:437-445.
17. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA. 2003;100:1891-1895.
18. Laverman P, Behe M, Oyen WJ, et al. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem. 2004;15:561-568.
19. Gotthardt M, Fischer M, Naeher I, et al. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. Eur J Nucl Med Mol Imaging. 2002;29: 597-606.
20. Janssen M, Frielink C, Dijkgraaf I, et al. Improved tumor targeting of radiolabeled ROD peptides using rapid dose fractionation. Cancer Biother Radiopharm. 2004;19:399-404.
21. Zhang H, Chen J, Waldherr C, et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res. 2004;64:6707-6715.
22. 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer. Eur J Nucl Med Mol Imaging. 2003;30:1134-1139.
23. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: current status and future directions. Eur J Nucl Med Mol Imaging. 2003;30:463-469.
24. Boerman OC, Griffiths GL, Oosterwijk JC, et al. Two-step targeting of RCC tumors in mice: improved tumor uptake and retention with bivalent chelate [abstract]. J Nucl Med. 1998;39(suppl):78P.
25. Boerman OC, Kranenborg MH, Oosterwijk E, et al. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999;59:4400-4405.
26. Lange PH, Vessella RL, Chiou RK, et al. Monoclonal antibodies in human renal cell carcinoma and their use in radioimmune localization and therapy of tumor xenografts. Surgery. 1985;98:143-150.
27. Chiou RK, Vessella RL, Elson MK, et al. Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. Cancer Res. 1985;45:6140-6146.
28. van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, et al. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(ln) antibody in 3 RCC models. J Nucl Med. 2005;46:495-501.
29. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 1990;9:253-266.
30. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding site barrier. J Nucl Med. 1990;31:1191-1198.
31. Sharkey RM, Karacay H, Richel H, et al. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res. 2003;9: 3897S-38913S.
32. Sands H, Jones PL, Shah SA, Palme D, Vessella RL, Gallagher BM. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res. 1988;48:188-193.
33. Blumenthal RD, Sharkey RM, Kashi R, Goldenberg DM. Suppression of tumor vascular activity by radioantibody therapy: implications for multiple cycle treatments. Sel Cancer Ther. 1991;7:9-16.
34. Blumenthal RD, Sharkey RM, Kashi R, Natale AM, Goldenberg DM. Physiological factors influencing radioantibody uptake: a study of four human colonic carcinomas. Int J Cancer. 1992;51:935-941.
35. Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30:1358-1366.
36. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med. 2005;46(suppl):115S-127S.
37. Weiden PL, Breitz HB, Press O, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000; 15:15-29.
38. Forera A, Weiden PL, Vose JM, et al. Phase I trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Blood. 2004;104:227-236.